Clinical Scorecard: OMNI Ultra Makes AAO Debut
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: OMNI Ultra Makes AAO Debut |
| Key Mechanisms | The system combines canaloplasty and trabeculotomy and is designed to address resistance associated with the trabecular meshwork, Schlemm's canal, and collector channels. |
| Target Population | Patients or participants described in the source article. |
| Care Setting | Care setting described in the source article. |
Key Highlights
- OMNI Ultra is the latest addition to Sight Sciences' implant-free glaucoma surgery platform.
- The system enables circumferential canaloplasty in a single pass, followed by trabeculotomy.
- TruSync Plus automatically delivers viscoelastic during microcatheter advancement and retraction.
- The procedure uses a clear corneal microincision and leaves no implant in the eye.
- Sight Sciences announced commercial availability ahead of the system's debut at the 2026 AAO Annual Meeting.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Adults with primary open-angle glaucoma; the article does not provide further patient-selection criteria.
The implant-free procedure combines canaloplasty and trabeculotomy through a clear corneal microincision. The article provides no comparative outcomes or adverse-event data.
Clinical Best Practices
- The article describes a surgical device and does not provide clinical practice guidelines or procedural recommendations beyond its intended use.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
